Synthesis and biological activity of polyethylene glycol-mouse nerve growth factor conjugate

Bioconjugate Chemistry

Volumn 10, Issue 6, 1999, Pages 932-937

  Belcheva, Nadya ^a   Woodrow Mumford, Kim ^a   Mahoney, Melissa J ^a   Saltzman, W Mark ^a  

^a School of Operations Research and Industrial Engineering   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOACTIVITY; BIOSYNTHESIS; CHEMICAL MODIFICATION; MAMMALS; NEURODEGENERATIVE DISEASES; NEURONS; PROTEINS;

ALZHEIMERS DISEASE; DIMERIC PROTEINS; NERVE GROWTH FACTOR; NEURITE OUTGROWTH; PROTEIN STABILITY; RP-HPLC; SDS-PAGE; SPECTROFLUOROMETRY; THERAPEUTIC POTENTIALS; THERAPEUTIC PROTEIN;

POLYETHYLENE GLYCOLS;

EID: 0033230001     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc990001k     Document Type: Article

References (25)

1. Bäckman, C., Rose, G., Hoffer, B., Henry, M., Bartus, R., Frieden, P., and Granholm, A. (1996) Systemic administration of a nerve growth factor conjugate reverses age-related cognitive dysfunction and prevents cholinergic neuron atrophy. J. Neurosci. 16 (17), 5437-5442.
2. Charles, V., Mufson, E., Frieden, P., Bartus, R., and Kordower, J. (1996) Atrophy of cholinergic basal forewbrain neurons following excitotoxic cortical lesions is reversed by intravenous administration of an NGF conjugate. Brain Res. 728, 193-203.
3. Drinkwater, C., Barker, P., Suter, U., and Shooter, E. (1993) The carboxyl terminus of nerve growth factor is required for biological activity. J. Biol. Chem. 268 (31), 23202-23207.
4. Frieden, P., Walus, L., Watson, P., Doctrow, S., Kozarich, J., Bäckman, C., Bergman, H., Hoffer, B., Bloom, F., and Granholm, A. (1993) Blood-brain barrier penetration and in vivo activity of an NGF conjugate. Science 259 (15 January), 373-377.
5. Harris, M., and Zalipsky, S. (1997) Poly(ethylene glycol) chemistry and biological applications. ACS Symp. Ser. 680.
6. Hermanson, G., (1996) Zero-length Cross-linkers; Tags and Probes. Bioconjugate techniques, pp 169-186, 297-416, Academic Press, Inc.
7. Kasaian, M., Jacobberger J., and Neet K. (1994) Flow cytometric analysis of fluorescein-labeled nerve growth factor binding to A875 human melanoma cells. Exp. Cell Res. 210, 77-85.
8. Kordower, J., Charles, V., Bayer, R., Bartus, R., Putney, S., Walus, L., and Frieden, P. (1994) Intravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington disease. Proc. Natl. Acad. Sci. U.S.A. 91, 9077-9080.
9. Laemmli, U.K. (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (259), 680-685.
10. Levi, A., Shechter, Y., Neufeld, E., and Schlessinger, J. (1980) Mobility, clustering, and transport of nerve growth factor in embryonal sensory cells and in a sympathetic neuronal cell line. Proc. Natl. Acad. Sci. U.S.A. 77 (6), 3469-3473.
11. Mahoney, M., and W. M. Saltzman (1999) Cultures of cells from fetal rat brain: methods to control composition, morphology, and biochemical activity. Biotechnol. Bioeng. 62 (4), 461-467.
12. McDonald, N., Lapatto, R., Rust, J., Gunning, J., Wlodawer, A., and Blundell, T. (1991) New protein fold reveald by a 2.3-Ä resolution crystal structure of nerve growth factor. Nature 354, 411-414.
13. Nakajima, N., and Ikada, Y. (1995) Mechanism of amide formation by carbodiimide for bioconjugation in aqueous media. Bioconjugate Chem. 6, 123-130.
14. Olson, L. (1993) NGF and the treatment of Alzheimer's disease. Exp. Neurol. 124, 5-15.
15. Pardridge, W. M., Wu, D., and Sakane, T. (1998) Combined use of carboxyl-directed protein pegylation and vector-mediated blood-brain barrier drug delivery system optimizes brain uptake of brain-derived neurotrophic factor following intravenous administration. Pharm. Res. 15 (4), 576-582.
16. Robinson, R., Radziejewski, C., Stuart, D., and Jones, Y. (1995) Structure of the brain-derived neutrophic factor/neutrophin 3 heterodimer. Biochemistry 34 (13), 4139-4146.
17. Rosenberg, M., Hawrot, E., and Breakefield, X. (1986) Receptor binding activities of biotinylated derivatives of β-nerve growth factor. J. Neurochemistry 46 (2), 641-647.
18. Rosenberg, M., Breakefield, X., and Hawrot, E. (1987) Targeting of liposomes to cells bearing nerve growth factor receptors mediated by biotinylated nerve growth factor. J. Neurochem. 48 (3), 865-875.
19. Sakane, T., and Pardridge, W. M. (1997) Carboxyl-directed pegylation of brain-derived neurotrophic factor markedly reduces systemic clearance with minimal loss of biologic activity. Pharm. Res. 14 (8), 1085-1091.
20. Scott, S. A., and Crutcher, K. A. (1994) Nerve growth factor and Alzheimer's disease. Rev. Neurosci. 5 (3), 179-211.
21. Shamovsky, I., Ross, G., Riopelle, R., and Weaver, D. (1996) Theoretical studies on the bioactive conformation of nerve growth factor using VBMC - a novel variable basis Monte Carlo simulated annealing algorithm for peptides. J. Am. Chem. Soc. 118, 9743-9749.
22. Shearwater Polymers, Inc., Polyethylene Glycol derivatives, technical data.
23. Wlodawer, A., Hodgson, K., and Shooter, E. (1975) Crystallization of nerve growth factor from mouse submaxillary glands. Proc. Natl. Acad. Sci. U.S.A. 72 (3), 777-779.
24. Yuen, E., Howe, C., Li, Y., Holtzman, D., and Mobley, W. (1996) Nerve growth factor and the neurotrophic factor hypothesis. Brain Dev. 18, 362-368.
25. Zalipsky, S. (1995) Chemistry of poly(ethylene glycol) conjugates with biologically active molecules. Adv. Drug Deliv. Rev. 16, 157-182.